AstraZeneca said that Tagrisso (osimertinib) in a first line setting has shown significant progression-free survival (PFS) benefit that was preserved through subsequent lines of therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
A new type of cancer vaccine has shown promise in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.
A phase 3 study of Incyte’s epacadostat in combination with Merck’s Keytruda (pembrolizumab) in patients with unresectable or metastatic melanoma has failed meet to primary endpoint.
MyoKardia has started dosing in its phase 2 MAVERICK-HCM clinical trial of mavacamten, the company’s oral, allosteric modulator of cardiac myosin mavacamten candidate in symptomatic non-obstructive hypertrophic cardiomyopathy patients.
Sellas Life Sciences Group has reported a positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.
Pfizer sad its Tafamidis phase 3 transthyretin cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months
Protagonist Therapeutics said it is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).
Ablynx’s lupus erythematosus treatment vobarilizumab has failed to meet primary endpoint in the phase II dose-ranging study.
Mitsubishi Tanabe Pharma has partnered with Hitachi to improve the efficiency of clinical trials for the development of new drugs through the latter's artificial intelligence (AI) technology.
Roche has announced that its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) showed a clinically significant survival benefit in a phase III lung cancer study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.